TSPO and myeloid sarcoma: This is consistent with the observation that in non-relapsing MS patients, activation of myeloid cells in perilesional normal-appearing white matter—as measured by PET imaging of radioligand binding to translocator protein (TSPO)—is a significant predictor of disease progression [50].